Clinical Trials
Multiple clinical trials evaluate conditions involving redox balance, metabolic disorders, and vascular function, specifically targeting glucose-6-phosphate dehydrogenase deficiency, oxidative stress, dyslipidemias, metabolic syndrome, and alcoholism. Ranging from unassigned designs to Phase II evaluations, protocols investigate key parameters such as carbohydrate metabolism and pulmonary outcomes. Sponsored by academic institutions, medical centers, and government bodies—including Emory University, the University of Thessaly, and the National Institute on Alcohol Abuse and Alcoholism—these studies encompass completed, not yet recruiting, terminated, and unknown recruitment statuses.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05571748 | Not yet recruiting | G6PD Deficiency|Carbohydrate Metabolism Disorder|Oxidative Stress |
University of Thessaly |
2023-02 | Not Applicable |
| NCT05449249 | Completed | Healthy|Periodontitis |
Buchinger Wilhelmi Development & Holding GmbH|Buchinger Wilhelmi Clinic|University of Geneva Switzerland|King''s College London|ETH Zurich (Switzerland) |
2022-09-01 | Not Applicable |
| NCT04763499 | Terminated | Vascular Dilation |
University of California Davis |
2021-12-01 | Not Applicable |
| NCT04909489 | Unknown status | Traditional Chinese Medicine|Dyslipidemias|Syndrome |
Dongzhimen Hospital Beijing |
2021-04-21 | -- |
| NCT04483011 | Unknown status | Metabolic Syndrome|Premature Aging |
Bioenergy Life Science Inc.|KGK Science Inc.|University of Washington |
2019-10-25 | Not Applicable |
| NCT03060772 | Terminated | Alcoholism |
Emory University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
2018-01-03 | Phase 2 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- Triphosphopyridine nucleotide disodium salt Solubility in DMSO
- Triphosphopyridine nucleotide disodium salt Stock Solution
- Triphosphopyridine nucleotide disodium salt Storage
- Triphosphopyridine nucleotide disodium salt Stability
- Triphosphopyridine nucleotide disodium salt Molecular Weight
- Triphosphopyridine nucleotide disodium salt SMILES
- Triphosphopyridine nucleotide disodium salt CAS Number
- Triphosphopyridine nucleotide disodium salt Chemical Structure (2D and 3D)
- Triphosphopyridine nucleotide disodium salt SDS|MSDS